

## Non-Enzymatic Hydration, Amine Addition, and Oxidation Reactions of Aza-arene Oxides

Derek R. Boyd,<sup>\*a</sup> R. Jeremy H. Davies,<sup>b</sup> Robert Dunlop,<sup>a</sup> H. Patricia Porter,<sup>a</sup> Lynne Hamilton,<sup>a</sup> and John J. McCullough<sup>a</sup>


Departments of Chemistry<sup>a</sup> and Biochemistry,<sup>b</sup> The Queen's University of Belfast, Belfast BT9 5AG, U.K.

The 5,6- and 7,8-arene oxides of quinoline were found to undergo unusual addition reactions with water and primary amines at ambient temperature to yield *trans*-dihydrodiol and *trans*-hydroxyamine adducts respectively; oxygen atom addition yielded *N*-oxide and *trans*-5,6,7,8-dioxide derivatives.

Quinoline is a common environmental pollutant which is known to be both mutagenic and carcinogenic,<sup>1</sup> and to yield a range of mammalian metabolites including quinoline *N*-oxide,<sup>1,2</sup> quinoline 5,6-oxide (**1B**),<sup>3</sup> *trans*-5,6-dihydroxy-5,6-dihydroquinoline (**2B**),<sup>1-3</sup> and several quinolinols (2-, 3-, 6-, 8-hydroxyquinolines).<sup>1,2,4</sup>

Members of the polycyclic aromatic hydrocarbon (PAH) and azapolycyclic aromatic hydrocarbon (APAH) series have been found to follow common metabolic pathways in mammalian systems (Scheme 1).<sup>5-7</sup> All the isolated metabolites emanate from the initially formed arene oxide metabolite (**1**,

step a). Arene oxides (**1**) in the PAH series [exemplified by naphthalene 1,2-oxide, (**1A**)] have previously been found to yield *trans*-hydroxy-thioether adducts by both enzymatic [(**5A**), *e.g.* R = glutathione] and non-enzymatic [(**5A**), *e.g.* R = Et] methods<sup>6</sup> (step e). Similarly, in the present study, the quinoline arene oxides (**1B**) and (**1C**) were rapidly converted into the *trans*-hydroxy-thioether adducts [(**5B**, **5C**) R = Bu<sup>t</sup>, Bu<sup>t</sup>SH-H<sub>2</sub>O-NaOH, 70% yield] at ambient temperature. To date, however, no reports on the formation of *trans*-dihydrodiols [*e.g.* (**2A**)] by non-enzymatic reactions of arene oxides of type (**1**) are available. Similarly, although diol epoxides (**3**)



Scheme 1

formed in step c may undergo non-enzymatic addition reactions with amines,<sup>5</sup> to form amino-triols (**4**) (step d), the uncatalysed addition of amines to type (**1**) arene oxides has not previously been observed (Al<sub>2</sub>O<sub>3</sub>-catalysed addition of primary amines to non-K region arene oxides has been observed).<sup>8</sup>

The present communication reports on the non-enzymatic hydration (step b), amine addition (step g), and epoxidation (step f) or *N*-oxidation (**1B** → **1D**, **1C** → **1E**) reactions of arene oxides (**1**) in the polycyclic aza-arene series [exemplified by the 5,6-(**1B**) and 7,8-arene oxides (**1C**) of quinoline].

The base-catalysed addition of water to arene oxides (**1B**) and (**1C**) at ca. 20 °C was monitored by <sup>1</sup>H n.m.r. spectroscopy [300 MHz, 0.24 M KOH-D<sub>2</sub>O -Bu<sup>18</sup>OD (1 : 1)] and yielded the *trans*-dihydrodiols [(**2B**), *t*<sub>1/2</sub> 6 days] and [(**2C**), *t*<sub>1/2</sub> 4 days] respectively.† The lower stability of the *trans*-dihydrodiol (**2C**) led to some aromatization during isolation. This hydration reaction may be run at higher temperatures (40 °C) and thus provides a synthetically useful biomimetic route to the *trans*-dihydrodiol metabolite (**2B**) in isolated yields of ca. 50–55% after p.l.c. purification. These *trans*-dihydrodiols [(**2B**) and (**2C**)] have previously only been available by a synthetic route involving three additional steps.<sup>3</sup>

The addition of *n*-butylamine (p*K*<sub>a</sub> 10.61) and aniline (p*K*<sub>a</sub> 4.62) to arene oxides (**1B**) and (**1C**) at ambient temperature was found to yield mainly (>95%) the *trans*-hydroxyamine adducts [(**7B**), R = Bu or Ph] and [(**7C**), R = Bu or Ph] respectively. This addition reaction was found to be accelerated by using the amine as both solvent and nucleophile [e.g. *t*<sub>1/2</sub> = 6 h for addition of *n*-butylamine to quinoline 7,8-oxide (**1C**) at 40 °C]. The major product hydroxy amines [(**7B**), R = Bu or Ph; (**7C**), R = Bu or Ph] were isolated by p.l.c. (20–30% yield). Cellular amines including the nucleobases adenine and guanine which have been found to undergo non-enzymatic nucleophilic addition reactions with diol epoxide metabolites<sup>5</sup> (step d) may thus in principle also be capable of reacting directly with the arene oxide metabolites of quinoline (**1B**). The presence of a very small proportion (<5%) of the minor amine (or thiol) adducts formed by nucleophilic attack at the

benzylic position of arene oxides (**1B**) and (**1C**) suggests that non-enzymatic hydration reactions also occur by preferential (>95%) attack of the hydroxide anion at the allylic position as found during enzyme catalysed hydration.

A common feature of nucleophilic attack by hydroxide anion or amines on arene oxides (**1B**) and (**2B**) is the faster reactivity with the epoxide moiety at the 7,8-position compared with the 5,6-position. This is presumably due to the stronger electron withdrawing effect of the pyridine ring on the epoxide at the 7,8-position. The electronegativity of the nitrogen atom in aza-arene oxides (**1B**) and (**1C**) can account for this enhanced reactivity toward nucleophiles and their stability in the presence of acids compared with normal arene oxides, e.g. (**1A**). The latter stability is reflected in the direct (h.p.l.c.) detection of an arene oxide metabolite of type (**1**), i.e. quinoline 5,6-oxide (**1B**).<sup>3</sup>

While naphthalene 1,2-oxide (**1A**)<sup>9</sup> and naphthalene *trans*-1,2;3,4-dioxide (**6A**)<sup>7</sup> have been found as enzymatically formed mammalian metabolites of naphthalene, and as chemical oxidation products of naphthalene,<sup>10,11</sup> the use of naphthalene 1,2-oxide (**1A**) as substrate for metachloroperoxybenzoic acid (MCPBA) oxidation results in acid-catalysed aromatization rather than epoxidation to yield the arene dioxide (**6A**). Using sodium hypochlorite<sup>12</sup> (NaOCl-CH<sub>2</sub>Cl<sub>2</sub>-Bu<sub>4</sub>NHSO<sub>4</sub>, 2 days, room temp.) as oxidant, the quinoline arene oxides [(**1B**) and (**1C**)] gave the *trans*-dioxide [(**6B**)/(**6C**), 56% yield] without *N*-oxidation. In contrast, MCPBA oxidation of the arene oxides (**1B**) and (**1C**) yielded regioselectively the arene oxide-*N*-oxide derivatives [(**1D**), 82% yield] and [(**1E**), 51% yield] respectively with the *trans*-diepoxide [(**6B**), (**6C**)] as a very minor product only. Further MCPBA oxidation of these arene oxide-*N*-oxide products [(**1D**), (**1E**)] yielded the *trans*-dioxide-*N*-oxide [(**6D**)/(**6E**)]. Preliminary results on the regioselective acid catalysed hydration of the arene dioxide (**6**) indicate that this compound is a convenient diol epoxide (**3**) precursor.

It is widely accepted<sup>5</sup> that bay region epoxy diol metabolites of polycyclic aromatic hydrocarbons play a prominent role in the covalent modification of nucleic acids and that this is ultimately responsible for the mutagenic and carcinogenic activity. Since quinoline does not possess a bay region its mutagenic/carcinogenic activity relative to naphthalene may reflect the formation of other types of metabolites or may be

† A detailed kinetic and product analysis study<sup>13</sup> has recently shown that this hydration reaction can occur under both basic [compounds (**1B**) and (**1C**)] and acidic [compound (**1B**)] conditions.

due to enhanced reactivity of the epoxydiol metabolites of quinoline. Following our characterization of the presently reported new adducts arising from nucleophilic addition of water and amines, and the *trans*-dioxide or *N*-oxide oxidation products, formed from the arene oxides of quinoline [(1B), (1C)] it will be of considerable interest to evaluate their biological activity and to establish whether they constitute minor metabolites of quinoline *in vivo*.

We gratefully acknowledge financial support from the Cancer Research Campaign (J. J. McC.), D.E.N.I. (R. D. and L. H.), and The Queen's University of Belfast (H. P. P.).

Received, 29th September 1988; Com. 8/03883J

## References

- 1 E. J. La Voie, E. A. Adams, A. Shigematsu, and D. Hoffmann, *Carcinogenesis*, 1983, **4**, 1169 and references therein.
  - 2 M. Tada, K. Takahashi, and Y. Kawazoe, *Chem. Pharm. Bull.*, 1982, **30**, 3834.
  - 3 S. K. Agarwal, D. R. Boyd, H. P. Porter, W. B. Jennings, S. J. Grossman, and D. M. Jerina, *Tetrahedron Lett.*, 1986, **27**, 4253.
  - 4 B. Scheunemann, *Arch. Exp. Path. Pharm.*, 1923, **100**, 51.
  - 5 S. K. Agarwal, J. M. Sayer, H. J. C. Yeh, L. K. Pannell, B. D. Hilton, M. A. Pigott, A. Dipple, H. Yagi, and D. M. Jerina, *J. Am. Chem. Soc.*, 1987, **109**, 2497 and references therein.
  - 6 D. R. Boyd and D. M. Jerina in 'The Chemistry of Heterocyclic Compounds,' vol. 42, Part 3, 'Small Ring Heterocycles,' ed. A. Hassner, Wiley-Interscience, 1985, 197.
  - 7 M. G. Horning, W. G. Stillwell, G. W. Griffin, and W.-S. Tsang, *Drug Metab. Dispos.*, 1980, **8**, 404.
  - 8 G. H. Posner and D. Z. Rogers, *J. Am. Chem. Soc.*, 1977, **99**, 8214.
  - 9 D. M. Jerina, J. W. Daly, J. W. Daly, B. Witkop, P. Zaltzman-Nirenberg, and S. Udenfriend, *Biochemistry*, 1970, **9**, 147.
  - 10 M. N. Akhtar, D. R. Boyd, J. D. Neill, and D. M. Jerina, *J. Chem. Soc., Perkin Trans. 1*, 1980, 1693.
  - 11 K. Ishikawa and G. W. Griffin, *Angew. Chem., Int. Ed. Engl.*, 1977, **22**, 410.
  - 12 S. Krishnan, D. G. Kuhn, and G. A. Hamilton, *J. Am. Chem. Soc.*, 1977, **99**, 8121.
  - 13 D. R. Bushman, J. M. Sayer, D. R. Boyd, and D. M. Jerina, *J. Am. Chem. Soc.*, 1989, in the press.
-